×
Electromed SG&A Expenses 2010-2024 | ELMD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Electromed sg&a expenses from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
View More
Related Stocks
Company Name
Market
Cap
Thermo Fisher Scientific (TMO)
$210.3B
Intuitive Surgical (ISRG)
$183B
Alcon (ALC)
$46B
Edwards Lifesciences (EW)
$41.3B
IQVIA Holdings (IQV)
$39.4B
IDEXX Laboratories (IDXX)
$37.1B
DexCom (DXCM)
$28B
STERIS (STE)
$22.1B
SONOVA HOLDING (SONVY)
$22.1B
Waters (WAT)
$19.4B
Hologic (HOLX)
$18.8B
Sysmex ADR (SSMXY)
$11.6B
Fresenius Medical Care AG KGaA (FMS)
$11.2B
Teleflex (TFX)
$11.1B
Globus Medical (GMED)
$10.2B
Penumbra (PEN)
$8.2B
Glaukos (GKOS)
$7.6B
Masimo (MASI)
$7.6B
PROCEPT BioRobotics (PRCT)
$4.9B
Integer Holdings (ITGR)
$4.4B
LivaNova (LIVN)
$2.8B
Inari Medical (NARI)
$2.8B
TransMedics (TMDX)
$2.7B
Veracyte (VCYT)
$2.7B
Nihon Kohden (NHNKY)
$2.6B
Elekta AB (EKTAY)
$2.3B
Tandem Diabetes Care (TNDM)
$2.1B
RxSight (RXST)
$1.9B
Integra LifeSciences Holdings (IART)
$1.5B
Artivion (AORT)
$1.1B
Electromed SG&A Expenses 2010-2024 | ELMD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Electromed sg&a expenses from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Related Stocks
Company Name
Market Cap
Thermo Fisher Scientific (TMO)
$210.3B
Intuitive Surgical (ISRG)
$183B
Alcon (ALC)
$46B
Edwards Lifesciences (EW)
$41.3B
IQVIA Holdings (IQV)
$39.4B
IDEXX Laboratories (IDXX)
$37.1B
DexCom (DXCM)
$28B
STERIS (STE)
$22.1B
SONOVA HOLDING (SONVY)
$22.1B
Waters (WAT)
$19.4B
Hologic (HOLX)
$18.8B
Sysmex ADR (SSMXY)
$11.6B
Fresenius Medical Care AG KGaA (FMS)
$11.2B
Teleflex (TFX)
$11.1B
Globus Medical (GMED)
$10.2B
Penumbra (PEN)
$8.2B
Glaukos (GKOS)
$7.6B
Masimo (MASI)
$7.6B
PROCEPT BioRobotics (PRCT)
$4.9B
Integer Holdings (ITGR)
$4.4B
LivaNova (LIVN)
$2.8B
Inari Medical (NARI)
$2.8B
TransMedics (TMDX)
$2.7B
Veracyte (VCYT)
$2.7B
Nihon Kohden (NHNKY)
$2.6B
Elekta AB (EKTAY)
$2.3B
Tandem Diabetes Care (TNDM)
$2.1B
RxSight (RXST)
$1.9B
Integra LifeSciences Holdings (IART)
$1.5B
Artivion (AORT)
$1.1B